Closed-loop tACS Modulation for the Core Clinical Features of Drug Addiction (NCT06454474) | Clinical Trial Compass
CompletedNot Applicable
Closed-loop tACS Modulation for the Core Clinical Features of Drug Addiction
China21 participantsStarted 2024-06-30
Plain-language summary
Using specific EEG biomarkers in methamphetamine-dependent individuals, this study systematically probes the effect of closed-loop tACS based on brain states
Who can participate
Age range18 Years – 45 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Individuals aged between 18 and 45 years, irrespective of gender, having completed a minimum of 9 years of education and capable of effectively cooperating in questionnaire evaluations.
Meet the diagnostic criteria set forth by the DSM-V concerning the severity of amphetamine-type substance addiction.
A history of utilizing amphetamine-type substances for a duration not less than one year, with a frequency of use being at least once per week.
Consent to actively cooperate in the completion of subsequent follow-up assessments.
Exclusion Criteria:
Severe cognitive functional impairments manifested through a history of head trauma, cerebrovascular diseases, epilepsy, etc., or usage of cognitive enhancement drugs in the past 6 months; an intellectual disability with an IQ score less than 70.
A diagnosis of schizophrenia or other severe mental illnesses as per the DSM-5 criteria.
Abuse or dependence on other psychoactive substances (excluding nicotine) within the past 5 years.
Severe organic diseases that might compromise study participation. Contraindications to tACS, such as a history of epileptic seizures or the presence of metallic implants in proximity to the head.
What they're measuring
1
Change of Craving assessed by Visual Analog Scale (VAS)
Timeframe: through study completion, an average of 1 month